Not in yet, but curious: what’s the realistic path to regulatory milestones here? How do they plan to enroll enough Lynch patients given trial timelines, and what’s the expected cost/benefit versus existing prevention strategies like surveillance or drugs?
Feels like a setup for a volatility pop if this pans out. I’m eyeing $MRNA and $MODRNA for a quick swing before the next catalyst.
Cancer vaccines rarely translate; past track record is shaky.
Here's the context. Wall Street consensus was 85K — itself a downgrade from April's 115K. The prevailing narrative was: Iran conflict + oil shock + DOGE federal job cuts = labor market cooling. The Fed could afford to be patient. Rates would eventually come down.
172K shattered that narrative on three levels.
First, it confirmed the "war economy resilience" thesis. Despite a genuine geopolitical conflict that drove oil above $90, US private sector hiring accelerated. Healthcare added 40K+. Transportation and warehousing surged. The consumer economy is not breaking.
Second, it changes the Fed's calculus for June 17. Warsh now walks into his first press conference with a labor market running above trend, inflation still at 3.8% PCE and 6.0% PPI, and oil hovering near $93. A dovish statement becomes nearly impossible. The best-case scenario is a "neutral hold" — which the market will interpret as hawkish relative to prior expectations.
Third, and most importantly, it resets the discount rate for every high-multiple growth stock. At 4.54% on the 10-year, an 80x earnings AI stock needs to grow faster — or reprice lower. That math doesn't care about Broadcom's Q3 guide or Snowflake's AWS deal. It's pure arithmetic.
The NFP number didn't say AI is over. It said the free lunch is over. Growth has to justify valuation from here — not the other way around.
Holding MSFT and NVDA; not convinced this changes my thesis.
Kinda nervous—did I miss the reset?
Wait for a pullback or jump on this print?
Feels like the bulls are really flexing with these targets. Excited, but also a bit dizzy chasing $280s and $350s.
These targets look rich; NVDA could retest highs soon.
As an allocator, I’m not buying the $350 consensus. I’d rather cap exposure at 5-7% and add only on pullbacks. If NVDA slips under $260, I’ll rotate some AI weight to MSFT and AVGO.
In the micro-cap and meme space, this kind of pop usually rerates small-cap equities and options liquidity. If it sticks, we might see follow-through from SPY options, COIN, and even some SPACs, but it’s still ultra-volatile.
Scalping GME into resistance, tight stops.
This run feels like it’s still on. If volume keeps rolling in and bids stay aggressive, I’m leaning into the momentum, but I’m watching for a pullback to retest the recent swing low before adding.
